Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. announced today that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Caraway Therapeutics for a total potential consideration of up to $610 million .
Merck & Co , Inc to Acquire Caraway Therapeutics, Inc finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
The collaboration agreement will see the development and commercialization of the target, TMEM175 involved in Parkinson's disease and other neurodegenerative conditions.